Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Oncology Institute (TOI) EBIT Margin: 2020-2024

Historic EBIT Margin for Oncology Institute (TOI) over the last 5 years, with FY2024 value amounting to 15.28%.

  • Oncology Institute's EBIT Margin rose 79700.0% to 5.9% in Q3 2025 from the same period last year, while for Sep 2025 it was 8.92%, marking a year-over-year increase of 78400.0%. This contributed to the annual value of 15.28% for FY2024, which is 84700.0% up from last year.
  • As of FY2024, Oncology Institute's EBIT Margin stood at 15.28%, which was up 84700.0% from 23.75% recorded in FY2023.
  • Over the past 5 years, Oncology Institute's EBIT Margin peaked at 4.37% during FY2020, and registered a low of 32.46% during FY2022.
  • Its 5-year average for EBIT Margin is 19.69%, with a median of 22.59% in 2021.
  • Its EBIT Margin has fluctuated over the past 5 years, first tumbled by -182200bps in 2021, then surged by 87000bps in 2023.
  • Over the past 5 years, Oncology Institute's EBIT Margin (Annual) stood at 4.37% in 2020, then plummeted by -417bps to 22.59% in 2021, then plummeted by -44bps to 32.46% in 2022, then rose by 27bps to 23.75% in 2023, then soared by 36bps to 15.28% in 2024.
  • Its EBIT Margin was 15.28% in FY2024, compared to 23.75% in FY2023 and 32.46% in FY2022.